Pinatuzumab vedotin is an antibody-drug coupling (ADC) targeting CD22 containing the microtubule inhibitor monomethylauristatin E (MMAE) for studies related to diffuse large B-cell lymphoma.
Purity:
>98.0%
CAS Number:
[1313706-14-7]
Target:
Drug-Linker Conjugates for ADC
* VAT and and shipping costs not included. Errors and price changes excepted